{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:16:00Z","timestamp":1694625360723},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ZS Kardiologie"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00392-005-1407-7","type":"journal-article","created":{"date-parts":[[2006,1,13]],"date-time":"2006-01-13T21:25:24Z","timestamp":1137187524000},"page":"iv24-iv27","source":"Crossref","is-referenced-by-count":0,"title":["Risikoadaptierte Therapie von Gef\u00e4\u00dferkrankungen\u2014","Risk adapted therapy of vascular diseases\u2014basic therapy of dys- and hyperlipoproteinemia"],"prefix":"10.1007","volume":"94","author":[{"given":"S.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1407_CR1","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH et al (2004) Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495\u20131504","journal-title":"N Engl J Med"},{"key":"1407_CR2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Cleeman","year":"2001","unstructured":"Cleeman JI (2001) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary of the Third Report of the National Cholesterin Education Program (NCEP). JAMA 285 19:2486\u20132497","journal-title":"JAMA"},{"key":"1407_CR3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","volume":"357","author":"DIAS","year":"2001","unstructured":"DIAS (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905\u2013910","journal-title":"Lancet"},{"key":"1407_CR4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","volume":"354","author":"GISSI-Prevenzione","year":"1999","unstructured":"GISSI-Prevenzione Forschungsgruppe (1999) Nahrungserg\u00e4nzung mit mehrfach unges\u00e4ttigten n-3-Fetts\u00e4uren und Vitamin E nach Herzinfarkt: Ergebnisse der GISSI-Prevenzione-Studie. Lancet 354:447\u2013455","journal-title":"Lancet"},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s003920170203","volume":"90","author":"Gohlke","year":"2001","unstructured":"Gohlke H, K\u00fcbler W, Mathes P et al (2001) Empfehlungen zur umfassenden Risikoverringerung f\u00fcr Patienten mit koronarer Herzerkrankung, Gef\u00e4\u00dferkrankungen und Diabetes. Z Kardiol 90:148\u2013149","journal-title":"Z Kardiol"},{"key":"1407_CR6","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","volume":"162","author":"Grundy","year":"2002","unstructured":"Grundy SM, Vega GL, McGovern ME et al (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes; results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162:1568\u20131576","journal-title":"Arch Intern Med"},{"key":"1407_CR7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis; a randomized controlled trial. JAMA 291:1071\u20131080","journal-title":"JAMA"},{"key":"1407_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"MRC","year":"2002","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals; a randomised placebo-controlled trial (HPS) (2002). Lancet 360:7\u201322","journal-title":"Lancet"},{"key":"1407_CR9","first-page":"263","volume":"25","author":"Kluthe","year":"2000","unstructured":"Kluthe R, F\u00fcrst P, Hauner H et al (2000) Rationalisierungsschema 2000 des Berufsverbandes Deutscher Ern\u00e4hrungsmediziner (BDEM), der Deutschen Adipositas Gesellschaft, der Deutschen Akademie f\u00fcr Ern\u00e4hrungsmedizin (DAEM), der Deutschen Gesellschaft f\u00fcr Ern\u00e4hrung (DGE), der Deutschen Gesellschaft f\u00fcr Ern\u00e4hrungsmedizin (DGEM) und des Verbandes der Di\u00e4tassistenten\u2014Deutscher Berufsverband (VDD). Aktuel Ernaehr Med 25:263\u2013270","journal-title":"Aktuel Ernaehr Med"},{"key":"1407_CR10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy BM et al (2002) on behalf of the PROSPER study group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623\u20131630","journal-title":"Lancet"}],"container-title":["Zeitschrift f\u00fcr Kardiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-005-1407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-005-1407-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-005-1407-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-005-1407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T02:16:12Z","timestamp":1652494572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-005-1407-7"}},"subtitle":["Basistherapie der Dys- und Hyperlipoprotein\u00e4mie"],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":10,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s00392-005-1407-7","relation":{},"ISSN":["0300-5860","1435-1285"],"issn-type":[{"value":"0300-5860","type":"print"},{"value":"1435-1285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}